Gilvetmab
Based on 1 Customer Validation
Gilvetmab is a canine-derived anti-cPD-1 monoclonal antibody, as well as an immune activator/antitumor agent. Gilvetmab binds to canine PD-1, blocks the interaction of PD-1/PD-L1/L2, prevents immunosuppression, reactivates antitumor responses, induces tumor regression or disease stabilization, and may also trigger pseudoprogression. Gilvetmab can be used in research related to malignant melanoma and mast cell tumors.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.37%
- CAS No.: 1808081-43-7
- 분자량:147.71 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
Canine IgG2 kappa
Canine
|
cPD-1 |
Gilvetmab, a canine IgG2κ antibody, fails to support functional binding of adalimumab's variable regions to human TNF-α or canine TNF-α when used as a scaffold for the chimeric antibody Humivet-G1 in vitro[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Gilvetmab (6-10 mg/kg; i.v.; every 14-28 days) demonstrates an objective response rate of 46% and a median time to progression that was not reached in client-owned dogs with stages I-III mast cell tumor, with an acceptable safety profile[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Client-owned dogs (multiple breeds; 1-16.2 years of age, ≥3 kg body weight; 52% male, 48% female)[4]
-
Dosage:6 mg/kg; 10 mg/kg; 10 mg/kg (escalated after 5 treatments at 6 mg/kg)
-
Administration:i.v.; every 28 days (up to 5 treatments); every 14 days (up to 10 treatments); every 14 days (escalated dose, 5 additional treatments)
-
Result:Achieved an objective response rate (ORR) of 20% (95% CI, 7%-41%), with 2 complete responses (8%) and 3 partial responses (12%).
Observed stable disease in 40% (10/25) of dogs.
Reached a median time to progression (TTP) of 56 days.
Maintained 14% of dogs progression-free at the end of the study.
Exhibited initial tumor enlargement (50% and 92% increase from baseline) followed by regression in 2 dogs receiving 10 mg/kg every 14 days, consistent with pseudoprogression.
-
Animal Model:Client-owned dogs (multiple breeds; 6.4-13.1 years of age, ≥3 kg body weight; 50% male, 50% female)[4]
-
Dosage:6 mg/kg; 10 mg/kg; 10 mg/kg (escalated after 5 treatments at 6 mg/kg)
-
Administration:i.v.; every 28 days (up to 5 treatments); every 14 days (up to 10 treatments); every 14 days (escalated dose, 5 additional treatments)
-
Result:Achieved an objective response rate (ORR) of 46% (95% CI, 27%-67%), with 2 complete responses (8%) and 10 partial responses (38%).
Observed stable disease in 27% (7/26) of dogs.
Did not reach median time to progression (TTP).
Maintained 39% of dogs progression-free at the end of the study.
Observed responses across all tumor stages (50% ORR for stage I, 33.3% for stage II, 44.4% for stage III).
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG2-kappa
ELISA, FACS, Functional assay
-
Immobilized PD-1 Protein,Canine (HEK293, C-His, HYP73342A) can bind Gilvetmab. The EC50 for this effect is 287 ng/mL.
Chemical Information
-
CAS No. 1808081-43-7
-
Appearance Liquid
-
분자량 147.71 kDa
-
Color Colorless to light yellow
-
SMILES
[Gilvetmab]
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Magee K, et al. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. PloS one. 2021;16(8):e0255798. [Content Brief]
[2]. Xia YY, et al. Limited Clinical Efficacy with Potential Adverse Events in a Pilot Study of Autologous Adoptive Cell Therapy in Canine Oral Malignant Melanoma. Veterinary sciences. 2024 Mar 28;11(4):150. [Content Brief]
[3]. Wang J, et al. Current Review of Monoclonal Antibody Therapeutics in Small Animal Medicine. Animals : an open access journal from MDPI. 2025 Feb 07;15(4):472. [Content Brief]
[4]. Chon E, et al. Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor. Journal of veterinary internal medicine. 2026 May 04;40(3):aalag098. [Content Brief]
[5]. Lee CC, et al. Structure-based development of a canine TNF-α-specific antibody using adalimumab as a template. Protein science : a publication of the Protein Society. 2024 Feb;33(2):e4873. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Gilvetmab Related Classifications
HY-P99641 Related Classifications
Powered by Bioz